📊 ACAD Key Takeaways
Is Acadia Pharmaceuticals Inc. (ACAD) a Good Investment?
ACAD demonstrates strong operational fundamentals with exceptional profitability (36.5% net margin, 31.9% ROE) and healthy revenue growth of 11.9% YoY, driven by pharmaceutical operations in a stable sector. The company maintains a fortress balance sheet with minimal debt (0.0x D/E), strong liquidity (3.83x current ratio), and positive free cash flow generation of $105.1M, providing financial flexibility for R&D investments and shareholder returns.
ACADIA shows solid core fundamentals with double-digit revenue growth, strong gross margins, positive operating income, and an exceptionally strong balance sheet with no leverage. However, earnings quality looks mixed because net income is far above operating income while free cash flow remains modest relative to reported profits, suggesting some benefit may be non-operational or less cash-backed. The company appears financially healthy, but the durability of profit expansion needs confirmation in future filings.
Why Buy Acadia Pharmaceuticals Inc. Stock? ACAD Key Strengths
- Exceptional net profitability with 36.5% net margin and 31.9% ROE indicating efficient capital deployment
- Strong balance sheet with zero long-term debt and $177.7M cash position relative to $1.6B total assets
- Robust liquidity position with 3.83x current ratio and 3.43x quick ratio providing operational flexibility
- Positive free cash flow generation of $105.1M with 9.8% FCF margin supporting sustainability
- Revenue growth of 11.9% YoY in pharmaceutical sector demonstrates market demand and product traction
- Revenue grew 11.9% year over year while remaining profitable at the operating level
- Balance sheet is strong with $177.69M in cash, no meaningful long-term debt, and high liquidity ratios
- Gross margin of 63.9% and positive free cash flow indicate a scalable and cash-generating core business
ACAD Stock Risks: Acadia Pharmaceuticals Inc. Investment Risks
- Operating margin of 9.8% is significantly lower than net margin of 36.5%, suggesting potential operational leverage concerns or non-operating income reliance
- Net income flat YoY (0.0% growth) despite 11.9% revenue growth indicates margin compression or increased expenses that warrant investigation
- Capital intensity appears low ($4.7M capex) which may constrain long-term competitiveness in R&D-dependent pharmaceutical sector
- 7 Form 4 filings in last 90 days suggests elevated insider trading activity that warrants monitoring for potential concerns
- Net income of $391.00M appears unusually high relative to $104.81M of operating income, raising earnings quality concerns
- Free cash flow margin of 9.8% is much lower than net margin of 36.5%, suggesting profit conversion to cash is limited
- As a pharmaceutical company, growth and margins may be vulnerable to product concentration, competition, and regulatory execution
Key Metrics to Watch
- Operating margin trend and cost structure evolution relative to gross margin stability
- Net income growth acceleration to support revenue growth rate
- Research and development spending levels as percentage of revenue to ensure competitive R&D investment
- Free cash flow sustainability and deployment strategy (R&D, acquisitions, or capital returns)
- Gross margin maintenance amid potential pricing pressures or product mix changes
- Operating cash flow and free cash flow conversion relative to net income
- Revenue growth and operating margin sustainability
Acadia Pharmaceuticals Inc. (ACAD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.83x current ratio provides a solid financial cushion.
ACAD Profit Margin, ROE & Profitability Analysis
ACAD vs Healthcare Sector: How Acadia Pharmaceuticals Inc. Compares
How Acadia Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Acadia Pharmaceuticals Inc. Stock Overvalued? ACAD Valuation Analysis 2026
Based on fundamental analysis, Acadia Pharmaceuticals Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Acadia Pharmaceuticals Inc. Balance Sheet: ACAD Debt, Cash & Liquidity
ACAD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Acadia Pharmaceuticals Inc.'s revenue has grown significantly by 121% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.37 indicates the company is currently unprofitable.
ACAD Revenue Growth, EPS Growth & YoY Performance
ACAD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $250.4M | $32.8M | $0.20 |
| Q2 2025 | $242.0M | $26.7M | $0.16 |
| Q1 2025 | $205.8M | $16.6M | $0.10 |
| Q3 2024 | $211.7M | $32.8M | $0.20 |
| Q2 2024 | $165.2M | $1.1M | $0.01 |
| Q1 2024 | $118.5M | $16.6M | $0.10 |
| Q3 2023 | $130.7M | -$27.2M | $-0.17 |
| Q2 2023 | $134.6M | $1.1M | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Acadia Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
ACAD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Acadia Pharmaceuticals Inc. (CIK: 0001070494)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 7, 2026 | 4 | xslF345X06/form4-04072026_110411.xml | View → |
| Apr 7, 2026 | 4 | xslF345X06/form4-04072026_110435.xml | View → |
| Mar 26, 2026 | 4 | xslF345X06/form4-03262026_080310.xml | View → |
| Mar 26, 2026 | 4 | xslF345X06/form4-03262026_080306.xml | View → |
| Mar 26, 2026 | 4 | xslF345X06/form4-03262026_080308.xml | View → |
❓ Frequently Asked Questions about ACAD
What is the AI rating for ACAD?
Acadia Pharmaceuticals Inc. (ACAD) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACAD's key strengths?
Claude: Exceptional net profitability with 36.5% net margin and 31.9% ROE indicating efficient capital deployment. Strong balance sheet with zero long-term debt and $177.7M cash position relative to $1.6B total assets. ChatGPT: Revenue grew 11.9% year over year while remaining profitable at the operating level. Balance sheet is strong with $177.69M in cash, no meaningful long-term debt, and high liquidity ratios.
What are the risks of investing in ACAD?
Claude: Operating margin of 9.8% is significantly lower than net margin of 36.5%, suggesting potential operational leverage concerns or non-operating income reliance. Net income flat YoY (0.0% growth) despite 11.9% revenue growth indicates margin compression or increased expenses that warrant investigation. ChatGPT: Net income of $391.00M appears unusually high relative to $104.81M of operating income, raising earnings quality concerns. Free cash flow margin of 9.8% is much lower than net margin of 36.5%, suggesting profit conversion to cash is limited.
What is ACAD's revenue and growth?
Acadia Pharmaceuticals Inc. reported revenue of $1.1B.
Does ACAD pay dividends?
Acadia Pharmaceuticals Inc. does not currently pay dividends.
Where can I find ACAD SEC filings?
Official SEC filings for Acadia Pharmaceuticals Inc. (CIK: 0001070494) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACAD's EPS?
Acadia Pharmaceuticals Inc. has a diluted EPS of $2.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACAD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Acadia Pharmaceuticals Inc. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ACAD stock overvalued or undervalued?
Valuation metrics for ACAD: ROE of 31.9% (sector avg: 15%), net margin of 36.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ACAD stock in 2026?
Our dual AI analysis gives Acadia Pharmaceuticals Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ACAD's free cash flow?
Acadia Pharmaceuticals Inc.'s operating cash flow is $109.8M, with capital expenditures of $4.7M. FCF margin is 9.8%.
How does ACAD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 36.5% (avg: 12%), ROE 31.9% (avg: 15%), current ratio 3.83 (avg: 2).
Why is ACAD's return on equity (ROE) so high?
Acadia Pharmaceuticals Inc. has a return on equity of 31.9%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 36.5% net margin.